Invention Grant
- Patent Title: Osteoclast inhibitors for knee conditions
-
Application No.: US14967224Application Date: 2015-12-11
-
Publication No.: US09408861B2Publication Date: 2016-08-09
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: K&L Gates LLP
- Agent Brent A. Johnson; Louis C. Cullman
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/675 ; A61K31/663 ; A61K45/06 ; A61K9/00 ; A61K9/20
Abstract:
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Public/Granted literature
- US20160095871A1 Osteoclast Inhibitors for Knee Conditions Public/Granted day:2016-04-07
Information query
